Cyxone initiates first-in-human trial with T20K for the treatment of MS
Cyxone (publ.), a Swedish biotech in autoimmune diseases, today announced that the company starts its first-in-human, phase I, clinical trial with drug candidate T20K for the treatment of multiple sclerosis (MS) immediately following the authorities’ approval. Currently, the focus is the recruitment and screening of healthy male volunteers for the study.Cyxone’s application to start a first-in-human, phase I, trial with their prophylactic drug candidate T20K targeting multiple sclerosis (MS) has been approved by the accredited Ethics Committee and Central Commission on Research Involving